ASCO 2019 | Molecular imaging for prostate cancer salvage radiotherapy planning

Here, Jeremie Calais, MD, from the University of California, Los Angeles, CA, discusses results from a Phase III study (NCT03582774) looking at 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning (PSMA-SRT). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.